| 000 | 01827 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513144117.0 | ||
| 264 | 0 | _c19980730 | |
| 008 | 199807s 0 0 eng d | ||
| 022 | _a0143-3636 | ||
| 024 | 7 |
_a10.1097/00006231-199803000-00011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRyding, E | |
| 245 | 0 | 0 |
_aDopamine D2-receptor density in humans as assessed with SPET and the new high-affinity ligand 123I-NCQ298: a pilot study. _h[electronic resource] |
| 260 |
_bNuclear medicine communications _cMar 1998 |
||
| 300 |
_a263-70 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain _xblood supply |
| 650 | 0 | 4 | _aCerebrovascular Circulation |
| 650 | 0 | 4 |
_aDopamine Agonists _xpharmacokinetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHaloperidol _xanalogs & derivatives |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIodine Radioisotopes |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPerphenazine _xanalogs & derivatives |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 |
_aRadiopharmaceuticals _xpharmacokinetics |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xanalysis |
| 650 | 0 | 4 | _aRegional Blood Flow |
| 650 | 0 | 4 |
_aSalicylamides _xpharmacokinetics |
| 650 | 0 | 4 |
_aSchizophrenia _xdiagnostic imaging |
| 650 | 0 | 4 | _aTissue Distribution |
| 650 | 0 | 4 |
_aTomography, Emission-Computed, Single-Photon _xmethods |
| 700 | 1 | _aTuninger, E | |
| 700 | 1 | _aOhlsson, T | |
| 700 | 1 | _aSjöholm, H | |
| 700 | 1 | _aFreccero-Rosman, K | |
| 700 | 1 | _aLevander, S | |
| 700 | 1 | _aRosén, I | |
| 773 | 0 |
_tNuclear medicine communications _gvol. 19 _gno. 3 _gp. 263-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00006231-199803000-00011 _zAvailable from publisher's website |
| 999 |
_c9591897 _d9591897 |
||